Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong
10.3779/j.issn.1009-3419.2017.01.02
- VernacularTitle:山东地区非小细胞肺癌分子靶向治疗驱动基因表达情况及临床特征分析
- Author:
QIAO XIULI
1
;
AI DAN
;
LIANG HONGLU
;
MU DIANBIN
;
GUO QISEN
Author Information
1. 济南大学 山东省医学科学院医学与生命科学学院
- Keywords:
Lung neoplasms;
Molecular target therapy;
Epidermal growth factor receptor;
Echinoderm microtu-bule-associated protein-like 4-anaplastic lymphoma kinase;
ROS proto-oncogene 1;
Kirsten rat sarcoma viral oncogene
- From:
Chinese Journal of Lung Cancer
2017;20(1):14-20
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Molecular targeted therapy has gradually become an important treatment for lung cancer, the aim of this research is to analyze the clinicopathologic features associated with the gene mutation status of epidermal growth factor receptor (EGFR), echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) and Kirsten rat sarcoma viral oncogene (KARS) in non-small cell lung cancer (NSCLC) patients and determine the most likely populations to beneift from molecular target ther-apy treatment. Methods hTe mutation status of EGFR, EML4-ALK fusion gene, ROS1 and AKRS gene were determined by Real-time PCR, the relationship between clinical pathologic features and concomitant gene were analyzed withχ2 test by SPSS sotfware 19.0. Results A total of 514 specimens from Shandong tumor hospital were collected from NSCLC patients between January 2014 and May 2016. The total mutation rate of EGFR gene was 36.70%, major occurred in exon 19 (36.61%) and exon 21 (51.36%), respectively, and EGFR mutations usually occurred in female, non-smoking and adenocarcinoma patients (P<0.05). hTe total rearrangements rate of EML4-ALK fusion gene was 9.37%, EML4-ALK fusion gene usually occurred in younger age (≤60 yr) and non-smoking patients (P<0.05). Mutations were not related to gender and pathological type (P>0.05). ROS1 fusion gene was detected in 136 cases, the positive rate was 3.67%, all patients were 60 years old, and the difference was statistically signiifcant (P<0.05). Only 23 samples were tested AKRS gene mutations, two of them were positive and the posi-tive rate was 8.70%. hTey all occurred in non-smoker and adenocarcinoma patients. No mutation was detected to coexist in EGFR, EML4-ALK and AKRS gene mutation. Conclusion EGFR, EML4-ALK, ROS1 and KARS deifnes different molecular subset of NSCLC with distinct characteristic, which provides a new option for the clinical treatment of patients with NSCLC.
